Sarah Patel's Avatar
published in Blogs
Jan 03, 2023
Chemomab Therapeutics (CMMB, $3.68) shares jump, on Phase 2a trial results for CM-101

Chemomab Therapeutics (CMMB, $3.68) shares jump, on Phase 2a trial results for CM-101

Chemomab Therapeutics Ltd shares jumped on Tuesday, after it reported topline results from its Phase 2a trial assessing CM-101 in non-alcoholic steatohepatitis (NASH) patients.

While the trial met its primary endpoint of safety and tolerability, CM-101 achieved reductions in secondary endpoints that include   liver fibrosis biomarkers and physiologic assessments measured at baseline and week 20.

Patients treated with CM-101 showed more significant improvements than the group that was given placebo treatment, in several liver fibrosis-related biomarkers.

Around 60% of CM-101-treated patients responded in at least three biomarkers at week 20, while no patients did  in the placebo group. A higher percentage of patients in the CM-101-treated group showed improvement in a physiologic measure of liver stiffness compared to the placebo group.

Related Tickers: CMMB